{"id":"procrit","rwe":[],"tags":[],"phase":"discontinued","safety":{"boxedWarnings":[],"safetySignals":[],"drugInteractions":[],"commonSideEffects":[],"contraindications":[],"specialPopulations":{},"discontinuationRates":[],"seriousAdverseEvents":[]},"status":"discontinued","trials":["NCT01394991","NCT00117247","NCT01783847","NCT00093015","NCT00501917","NCT02263833","NCT02075463","NCT01628107","NCT01587898","NCT00254436","NCT02049346","NCT00036400","NCT00081471","NCT00344409","NCT02481843","NCT00122720","NCT00117624","NCT00642850","NCT00577096","NCT00550680","NCT03401710","NCT00831220","NCT00072059","NCT01962571","NCT05810311","NCT02361931","NCT00546481","NCT03919500","NCT05704894","NCT00224003","NCT00527215","NCT01154491","NCT01383460","NCT03223961","NCT06919861","NCT01695746","NCT01105494","NCT04707768","NCT00236678","NCT00000587","NCT00394953","NCT00220675","NCT00711958","NCT00004917","NCT03693950","NCT00854217","NCT00437450","NCT05301517","NCT02764736","NCT02002039"],"aliases":["Epoetin Alfa","Epogen"],"patents":[],"pricing":[],"offLabel":[],"timeline":[],"aiSummary":"","brandName":"Procrit","companyId":"university-of-louisville","ecosystem":[],"mechanism":{"target":"Erythropoietin receptor","novelty":"","modality":"Small molecule","drugClass":"","explanation":"","oneSentence":"","technicalDetail":""},"commercial":null,"references":[],"biosimilars":[],"companyName":"University of Louisville","competitors":[],"dataSources":[{"url":"https://clinicaltrials.gov","name":"ClinicalTrials.gov","fields":["trialDetails","trials"],"retrievedDate":"2026-04-07"},{"url":"https://drugcentral.org","name":"DrugCentral","fields":["indications","contraindications","safety","target","drugInteractions"],"retrievedDate":"2026-04-07"}],"genericName":"Procrit","indications":{"approved":[{"name":"Anemia due to chemotherapy","diseaseId":"anemia-due-to-chemotherapy","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Anemia in chronic kidney disease","diseaseId":"anemia-in-chronic-kidney-disease","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"}],"offLabel":[],"pipeline":[]},"labelChanges":[],"relatedDrugs":[],"trialDetails":[{"nctId":"NCT01394991","phase":"Phase 4","title":"A Randomized, Open-Label, Multicenter Study Evaluating Thrombovascular Events in Subjects With Cancer Receiving Chemotherapy and Administered Epoetin Alfa Once or Three Times a Week for the Treatment ","status":"COMPLETED","sponsor":"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.","isPivotal":false,"enrollment":504,"indication":"Anemia, Neoplasms","completionDate":"2009-09"},{"nctId":"NCT00117247","phase":"Phase 1","title":"A Study to Assess the Pharmacokinetics and Pharmacodynamics of Repeat-Sose Subcutaneous Darbepoetin Alfa in Subjects With Congestive Heart Failure and Anemia, and a Single Dose in Healthy Age- and Sex","status":"COMPLETED","sponsor":"Amgen","isPivotal":false,"enrollment":0,"indication":"Anemia, Congestive Heart Failure","completionDate":"2004-07"},{"nctId":"NCT01783847","phase":"Phase 1","title":"Study of Visual Recovery After Erythropoietin (EPO) Injection, in Patients With Traumatic Optic Neuropathy (TON)","status":"COMPLETED","sponsor":"Tehran University of Medical Sciences","isPivotal":false,"enrollment":117,"indication":"Traumatic Optic Neuropathy","completionDate":"2017-02"},{"nctId":"NCT00093015","phase":"Phase 3","title":"Trial to Reduce Cardiovascular Events With Aranesp® Therapy","status":"COMPLETED","sponsor":"Amgen","isPivotal":true,"enrollment":4038,"indication":"Kidney Disease, Diabetes Mellitus","completionDate":"2009-07-01"},{"nctId":"NCT00501917","phase":"Phase 2","title":"Single Center, Prospective, Randomized, Partly-Double Blinded, Controlled Trial to Assess the Safety and Feasibility of Intracoronary Cell Infusion Mobilized With G-CSF and Darbepoetin and Their Effec","status":"UNKNOWN","sponsor":"Seoul National University Hospital","isPivotal":true,"enrollment":116,"indication":"Acute Myocardial Infarction","completionDate":"2010-02"},{"nctId":"NCT02263833","phase":"N/A","title":"Post Marketing Surveillance of Mircera®","status":"COMPLETED","sponsor":"Hoffmann-La Roche","isPivotal":false,"enrollment":748,"indication":"Kidney Disease, Chronic","completionDate":"2012-08"},{"nctId":"NCT02075463","phase":"Phase 2","title":"A 16-week, Phase 2a, Single-arm, Multi-center, Open-label Study to Evaluate the Safety and Efficacy of GSK1278863 After Switching From Recombinant Human Erythropoietin (rhEPO), in Hemodialysis-depende","status":"TERMINATED","sponsor":"GlaxoSmithKline","isPivotal":false,"enrollment":15,"indication":"Anemia","completionDate":"2016-03-16"},{"nctId":"NCT01628107","phase":"Phase 3","title":"A Phase III, Open-label, Multicenter, Long-term Safety Study Of Intravenous Epoetin Hospira In Patients With Chronic Renal Failure Requiring Hemodialysis And Receiving Epoetin Maintenance Treatment","status":"COMPLETED","sponsor":"Pfizer","isPivotal":true,"enrollment":406,"indication":"Chronic Renal Failure Requiring Hemodialysis","completionDate":"2015-01-02"},{"nctId":"NCT01587898","phase":"Phase 2","title":"A Four-week Phase IIa, Randomized, Double-blind, Placebo-controlled, Parallel-group, Multi-center Study to Evaluate the Safety, Efficacy and Pharmacokinetics of GSK1278863 in Subjects With Anemia Asso","status":"COMPLETED","sponsor":"GlaxoSmithKline","isPivotal":false,"enrollment":72,"indication":"Anaemia","completionDate":"2013-05-07"},{"nctId":"NCT00254436","phase":"Phase 3","title":"A Double-Blind, Randomized, Placebo-Controlled Study of the Efficacy and Safety of Epoetin Alfa Administered Weekly in Patients With Gastric or Rectal Cancers Undergoing Preoperative Chemoradiation Fo","status":"TERMINATED","sponsor":"M.D. Anderson Cancer Center","isPivotal":true,"enrollment":50,"indication":"Gastrointestinal Cancer, Rectal Cancer","completionDate":"2004-06-29"},{"nctId":"NCT02049346","phase":"Phase 4","title":"Erythropoietins in Management of Anemia of End Stage Renal Disease: A Prospective Study From Qatar.","status":"COMPLETED","sponsor":"Hamad Medical Corporation","isPivotal":false,"enrollment":327,"indication":"Anemia of End Stage Renal Disease","completionDate":"2013-06"},{"nctId":"NCT00036400","phase":"Phase 3","title":"A Double-Blind, Randomized, Placebo-Controlled Study of the Efficacy and Safety of Epoetin Alfa Administered Weekly in Patients With Gastric or Rectal Cancers Undergoing Preoperative Chemoradiation Fo","status":"COMPLETED","sponsor":"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.","isPivotal":true,"enrollment":60,"indication":"Stomach Neoplasms, Rectal Neoplasms","completionDate":"2003-12"},{"nctId":"NCT00081471","phase":"Phase 3","title":"A Randomized, Open-label Study of the Effect of Subcutaneous Mircera on Hemoglobin Level/Correction in Non-dialysis Patients With Chronic Kidney Disease","status":"COMPLETED","sponsor":"Hoffmann-La Roche","isPivotal":true,"enrollment":324,"indication":"Anemia","completionDate":"2006-07"},{"nctId":"NCT00344409","phase":"Phase 3","title":"A Double-blind, Placebo Controlled, Randomized Study of KRN321 for the Treatment of Anemia in Cancer Patients","status":"COMPLETED","sponsor":"Kyowa Kirin Co., Ltd.","isPivotal":true,"enrollment":200,"indication":"Anemia","completionDate":""},{"nctId":"NCT02481843","phase":"N/A","title":"Hyperoxia, Erythropoiesis and Tissue Oxygenation in Critically Ill Patient","status":"COMPLETED","sponsor":"Università Politecnica delle Marche","isPivotal":false,"enrollment":40,"indication":"Respiratory Failure","completionDate":"2015-03"},{"nctId":"NCT00122720","phase":"Phase 4","title":"The Effect of Darbepoetin Alfa Treatment Upon the Rehabilitation Following Planned Surgery for Colorectal Cancer","status":"COMPLETED","sponsor":"Herning Hospital","isPivotal":false,"enrollment":200,"indication":"Colorectal Cancer","completionDate":"2006-01"},{"nctId":"NCT00117624","phase":"Phase 3","title":"A Randomized, Double-Blind, Study of Front-Loading Darbepoetin Alfa Compared With Standard Weekly Administration for the Treatment of Anemia in Subjects With a Non-Myeloid Malignancy and Receiving Mul","status":"COMPLETED","sponsor":"Amgen","isPivotal":true,"enrollment":0,"indication":"Anemia","completionDate":"2003-12"},{"nctId":"NCT00642850","phase":"Phase 3","title":"A Single Arm, Open Label Study to Assess the Efficacy, Safety and Tolerability of Once-monthly Administration of Intravenous C.E.R.A. for the Maintenance of Haemoglobin Levels in Dialysis Patients Wit","status":"COMPLETED","sponsor":"Hoffmann-La Roche","isPivotal":true,"enrollment":188,"indication":"Anemia","completionDate":"2009-07"},{"nctId":"NCT00577096","phase":"NA","title":"Effects of Exercise in Combination With Epoetin Alfa During High-Dose Chemotherapy and Autologous Peripheral Blood Stem Cell Transplantation for Multiple Myeloma","status":"COMPLETED","sponsor":"University of Arkansas","isPivotal":false,"enrollment":120,"indication":"Multiple Myeloma","completionDate":"2004-06"},{"nctId":"NCT00550680","phase":"Phase 3","title":"A Single Arm, Open Label Study to Assess the Efficacy, Safety, and Tolerability of Once-Monthly Administration of Intravenous C.E.R.A. for the Maintenance of Haemoglobin Levels in Dialysis Patients Wi","status":"COMPLETED","sponsor":"Hoffmann-La Roche","isPivotal":true,"enrollment":208,"indication":"Chronic Renal Anemia","completionDate":"2009-09"},{"nctId":"NCT03401710","phase":"NA","title":"Erythropoietin Role in Acute Kidney Injury (EAKI): a Pragmatic Clinical Trial","status":"TERMINATED","sponsor":"Saint-Joseph University","isPivotal":false,"enrollment":134,"indication":"Anemia Renal","completionDate":"2021-08-25"},{"nctId":"NCT00831220","phase":"N/A","title":"Endothelial Dysfunction in Chronic Obstructive Pulmonary Disease","status":"COMPLETED","sponsor":"Hospital Universitari Son Dureta","isPivotal":false,"enrollment":99,"indication":"Chronic Obstructive Pulmonary Disease, Endothelial Dysfunction","completionDate":"2007-10"},{"nctId":"NCT00072059","phase":"Phase 2","title":"An Open Label, Randomized, Multicenter, Phase II Study To Determine Hemoglobin Dose Response, Safety And Pharmacokinetic Profile Of Ro 50-3821 Given Subcutaneously Once Weekly Or Once Every 3 Weeks To","status":"COMPLETED","sponsor":"Jonsson Comprehensive Cancer Center","isPivotal":false,"enrollment":0,"indication":"Anemia, Lung Cancer","completionDate":"2005-02"},{"nctId":"NCT01962571","phase":"Phase 3","title":"Treatment of Optic Neuritis With Erythropoietin: a Randomised, Double-blind, Placebo-controlled Trial","status":"COMPLETED","sponsor":"University Eye Hospital, Freiburg","isPivotal":true,"enrollment":108,"indication":"Optic Neuritis","completionDate":"2019-11-26"},{"nctId":"NCT05810311","phase":"Phase 2","title":"The Effect of Roxadustat on the Levels of Renal Oxygenation in Patients With Diabetes Nephropathy (FOXTROT)","status":"NOT_YET_RECRUITING","sponsor":"Region Stockholm","isPivotal":false,"enrollment":30,"indication":"Diabetes Complications, Diabetes; Nephropathy (Manifestation)","completionDate":"2027-12-31"},{"nctId":"NCT02361931","phase":"Phase 1","title":"Prospective, Multicenter, Single-blind, Randomized, Controlled Clinical Trial on Safety and Efficacy of a Novel Topical Formulation Containing Erythropoietin for the Treatment of Diabetic Foot Ulcers","status":"COMPLETED","sponsor":"Remedor Biomed Ltd","isPivotal":false,"enrollment":20,"indication":"Diabetic Foot Ulcer","completionDate":"2018-06-12"},{"nctId":"NCT00546481","phase":"Phase 3","title":"An Open-label, Randomized, Multi-center, Parallel Group Study to Demonstrate Correction of Anemia Using Intravenous Injections of RO0503821 in Patients With Chronic Kidney Disease Who Are on Dialysis","status":"COMPLETED","sponsor":"Hoffmann-La Roche","isPivotal":true,"enrollment":80,"indication":"Anemia","completionDate":"2009-12"},{"nctId":"NCT03919500","phase":"Phase 2","title":"Erythropoietin Protects Very Preterm Infants Against Necrotizing Enterocolitis","status":"COMPLETED","sponsor":"Zhengzhou University","isPivotal":false,"enrollment":1285,"indication":"Premature Infant","completionDate":"2019-04"},{"nctId":"NCT05704894","phase":"Phase 3","title":"Phase III Study, Multi-center, Open, Randomized, to Assess the Impact of Early Starting Erythropoetin in the Reduction of Transfusions Blood and Improvement of Quality of Life and Fatigue in Children ","status":"UNKNOWN","sponsor":"Blau Farmaceutica S.A.","isPivotal":true,"enrollment":320,"indication":"Anemia, Neoplasms","completionDate":"2025-11"},{"nctId":"NCT00224003","phase":"Phase 4","title":"Open-Label, Multi-Center Study of the Safety and Efficacy of Ferrlecit® in the Maintenance of Iron Stores in Pediatric Hemodialysis Patients Receiving Epoetin","status":"COMPLETED","sponsor":"Watson Pharmaceuticals","isPivotal":false,"enrollment":23,"indication":"Anemia","completionDate":"2005-02"},{"nctId":"NCT00527215","phase":"Phase 2","title":"A Study of Darbepoetin Alfa Administered Once Every Four Weeks in Chronic Renal Insufficiency (CRI) Subjects With Anemia","status":"COMPLETED","sponsor":"Amgen","isPivotal":false,"enrollment":98,"indication":"Pre-Dialysis","completionDate":"2003-10"},{"nctId":"NCT01154491","phase":"Phase 3","title":"Multicenter Double-bind Randomized Trial of Ferric Carboxymaltose With or Without Erythropoietin for the Prevention of Red-cell Transfusion in Hip Fracture Perioperative Period.","status":"COMPLETED","sponsor":"Fundación Pública Andaluza para la gestión de la Investigación en Sevilla","isPivotal":true,"enrollment":303,"indication":"Hip Fractures","completionDate":"2013-05"},{"nctId":"NCT01383460","phase":"Phase 3","title":"Randomized Placebo-controlled Trial to Assess the Efficacy of Granulocyte Colony-stimulating Factor (G-CSF) and Erythropoetin (EPO) in the Survival of Patients With Acute-on-chronic Liver Failure (ACL","status":"COMPLETED","sponsor":"Institute of Liver and Biliary Sciences, India","isPivotal":true,"enrollment":55,"indication":"Acute on Chronic Hepatic Failure","completionDate":"2013-01"},{"nctId":"NCT03223961","phase":"Phase 3","title":"A Randomized Trial Testing Early vs Late Onset of EPO Alfa Treatment in Lower Risk MDS With Non RBC Transfusion Dependent Anemia and Without Del 5q","status":"ACTIVE_NOT_RECRUITING","sponsor":"Groupe Francophone des Myelodysplasies","isPivotal":true,"enrollment":124,"indication":"Myelodysplastic Syndromes","completionDate":"2028-10-01"},{"nctId":"NCT06919861","phase":"Phase 1","title":"A Randomized, Double-blind, Two-group Crossover Study Comparing the Pharmacokinetics, Pharmacodynamics, and Safety of Nanokine (Nanogen) With Eprex® (Janssen-Cilag Ltd) in Healthy Male Volunteers","status":"NOT_YET_RECRUITING","sponsor":"Nanogen Pharmaceutical Biotechnology Joint Stock Company","isPivotal":false,"enrollment":44,"indication":"Natural Blood and Blood Product Toxicity","completionDate":"2025-12"},{"nctId":"NCT01695746","phase":"N/A","title":"Efficacy of Methoxy Poly-Ethylene Glycol Epoetin Beta (C.E.R.A.) for Correction of Anemia and Maintenance of the Hb Levels in CKD Patients in Stage III - IV, Not on Dialysis, Treated According to Rout","status":"COMPLETED","sponsor":"Hoffmann-La Roche","isPivotal":false,"enrollment":108,"indication":"Anemia","completionDate":"2013-11"},{"nctId":"NCT01105494","phase":"N/A","title":"Prospective Study Evaluating the Quality of Life in Dialysis Patients With End Stage Renal Disease","status":"COMPLETED","sponsor":"Hoffmann-La Roche","isPivotal":false,"enrollment":6000,"indication":"Anemia","completionDate":"2012-06"},{"nctId":"NCT04707768","phase":"Phase 3","title":"A Randomized, Open-label, Active-controlled Study Evaluating the Efficacy and Safety of Dose Conversion From a Long-acting Erythropoiesis-stimulating Agent (Mircera®) to Three Times Weekly Oral Vadadu","status":"COMPLETED","sponsor":"Akebia Therapeutics","isPivotal":true,"enrollment":456,"indication":"Anemia Associated With Chronic Kidney Disease (CKD)","completionDate":"2023-01-30"},{"nctId":"NCT00236678","phase":"Phase 2","title":"A Randomized, Double-blind, Placebo-controlled Study to Assess Fatigue in Patients With Anemia of Chronic Disease (ACD) Due to Rheumatoid Arthritis Receiving PROCRIT� (Epoetin Alfa)","status":"TERMINATED","sponsor":"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.","isPivotal":false,"enrollment":29,"indication":"Anemia, Rheumatoid Arthritis","completionDate":"2006-01"},{"nctId":"NCT00000587","phase":"Phase 2","title":"","status":"COMPLETED","sponsor":"Thomas Jefferson University","isPivotal":false,"enrollment":0,"indication":"Acquired Immunodeficiency Syndrome, Anemia","completionDate":"2005-01"},{"nctId":"NCT00394953","phase":"Phase 3","title":"A Randomized, Controlled, Open Label, Multicenter, Parallel-group Study to Compare the Effect of Mircera With That of Darbepoetin Alfa, Administered Intravenously at Extended Dosing Intervals, for the","status":"COMPLETED","sponsor":"Hoffmann-La Roche","isPivotal":true,"enrollment":490,"indication":"Anemia","completionDate":"2008-11"},{"nctId":"NCT00220675","phase":"Phase 2","title":"Recombinant Human Erythropoietin (r-HuEPO) in the Prevention of Neurologic Sequelae From Malignant Spinal Cord Compression: a Multi-Center, Placebo-Controlled, Phase 2 Randomized Study","status":"TERMINATED","sponsor":"Sunnybrook Health Sciences Centre","isPivotal":true,"enrollment":7,"indication":"Nerve Compression Syndromes","completionDate":"2007-07"},{"nctId":"NCT00711958","phase":"Phase 3","title":"Double-blind, Randomized, Multicenter, Clinical Phase III Study to Evaluate the Efficacy and Safety of HX575 for the Treatment of Chemotherapy Associated Anemia in Cancer Patients","status":"COMPLETED","sponsor":"Sandoz","isPivotal":true,"enrollment":114,"indication":"Anemia","completionDate":"2005-12"},{"nctId":"NCT00004917","phase":"Phase 3","title":"A Randomized Phase III Trial to Assess the Effect of Erythropoietin on Local-Regional Control in Anemic Patients Treated With Radiotherapy for Carcinoma of the Head and Neck","status":"COMPLETED","sponsor":"Radiation Therapy Oncology Group","isPivotal":true,"enrollment":0,"indication":"Anemia, Head and Neck Cancer","completionDate":"2016-12"},{"nctId":"NCT03693950","phase":"Phase 1","title":"A Double-blind, Randomized, Controlled Clinical Study of the Pharmacokinetics, Pharmacodynamics, Tolerability, and Safety of Multiple Intravenous Injections of BCD-066 and Aranesp® in Healthy Voluntee","status":"COMPLETED","sponsor":"Biocad","isPivotal":false,"enrollment":57,"indication":"Healthy","completionDate":"2017-07-03"},{"nctId":"NCT00854217","phase":"NA","title":"","status":"COMPLETED","sponsor":"Cliniques universitaires Saint-Luc- Université Catholique de Louvain","isPivotal":false,"enrollment":40,"indication":"Cardiac Surgery","completionDate":"2010-12"},{"nctId":"NCT00437450","phase":"Phase 2","title":"Treatment of the Anemia of Myelodysplastic Syndromes by the Association of Epoetin Beta and All Trans Retinoic Acid","status":"UNKNOWN","sponsor":"Groupe Francophone des Myelodysplasies","isPivotal":false,"enrollment":99,"indication":"Anemia in Myelodysplastic Syndromes","completionDate":"2005-09"},{"nctId":"NCT05301517","phase":"Phase 3","title":"A Randomized, Open-label, Active-controlled, Multicenter Phase 3 Study to Investigate the Efficacy and Safety of Roxadustat for Treatment of Anemia in Subjects Receiving Chemotherapy Treatment for Non","status":"COMPLETED","sponsor":"Kyntra Bio","isPivotal":true,"enrollment":159,"indication":"Chemotherapy Induced Anemia","completionDate":"2023-04-21"},{"nctId":"NCT02764736","phase":"NA","title":"Atorvastatin Reduces Chronic Inflammation and aVerage Epogen Dose (ARChIVED)","status":"WITHDRAWN","sponsor":"Albert Einstein Healthcare Network","isPivotal":false,"enrollment":0,"indication":"Complication of Renal Dialysis","completionDate":"2017-03-22"},{"nctId":"NCT02002039","phase":"Phase 2","title":"Erythropoietin in Perinatal Asphyxia: A Randomized Placebo Controlled Trial","status":"COMPLETED","sponsor":"Sheri Kashmir Institute of Medical Sciences","isPivotal":true,"enrollment":100,"indication":"Perinatal Asphyxia","completionDate":"2016-06"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"administration":{"icon":"","route":"","frequency":"","formulation":""},"formularyStatus":[],"apiManufacturers":[],"developmentCodes":[],"ownershipHistory":[],"therapeuticAreas":["Hematology"],"biosimilarFilings":[],"firstApprovalDate":"","companionDiagnostics":[],"firstApprovalCountry":null,"genericManufacturerList":[],"modality":"Small molecule","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"partial","dataCompleteness":{"mechanism":false,"indications":true,"safety":false,"trials":true,"score":2}}